These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Amyloidosis: current trends in its investigation. Cohen AS; Cathcart ES; Skinner M Arthritis Rheum; 1978; 21(1):153-60. PubMed ID: 414758 [No Abstract] [Full Text] [Related]
27. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). Glenner GG N Engl J Med; 1980 Jun; 302(23):1283-92. PubMed ID: 6154243 [No Abstract] [Full Text] [Related]
28. Light chain amyloidosis of the urinary bladder. A site restricted deposition of an externally produced immunoglobulin. Livneh A; Shtrasburg S; Martin BM; Baniel J; Gal R; Pras M J Clin Pathol; 2001 Dec; 54(12):920-3. PubMed ID: 11729210 [TBL] [Abstract][Full Text] [Related]
30. The classification and typing of amyloid deposits. Gertz MA Am J Clin Pathol; 2004 Jun; 121(6):787-9. PubMed ID: 15198347 [No Abstract] [Full Text] [Related]
32. Primary localized amyloidosis of the eyelid: two cases of immunoglobulin light chain-derived proteins, subtype lambda V respectively lambda VI. Olsen KE; Sandgren O; Sletten K; Westermark P Clin Exp Immunol; 1996 Nov; 106(2):362-6. PubMed ID: 8918586 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region. Hoshii Y; Kiyama M; Cui D; Kawano H; Ishihara T Pathol Int; 2006 Jun; 56(6):324-30. PubMed ID: 16704496 [TBL] [Abstract][Full Text] [Related]
34. Immunopathology of the amyloid diseases. Franklin EC Hosp Pract; 1980 Sep; 15(9):70-7. PubMed ID: 6773875 [TBL] [Abstract][Full Text] [Related]
35. Characterization of an amyloid fibril protein from localized amyloidosis of the skin as lambda immunoglobulin light chains of variable subgroup I (A lambda I). Husby G; Sletten K; Blumenkrantz N; Danielsen L Clin Exp Immunol; 1981 Jul; 45(1):90-6. PubMed ID: 6796317 [TBL] [Abstract][Full Text] [Related]
36. Amyloid fibril protein AA in Papua New Guinean amyloidosis. Anders RF; Price MA; Wilkey IS; Husby G; Takitaki F; Natvig JB; McAdam KP Clin Exp Immunol; 1976 Apr; 24(1):49-53. PubMed ID: 820500 [TBL] [Abstract][Full Text] [Related]
37. An investigation of the protein components of amyloid using immunoperoxidase and permanganate methods on tissue sections. Looi LM Pathology; 1986 Jan; 18(1):137-40. PubMed ID: 2425332 [TBL] [Abstract][Full Text] [Related]
38. [Typing of amyloidoses intra vitam by tissue biopsy using antibodies. Report on 2 patients]. Fischer JL; Cyran J; Linke RP Internist (Berl); 1986 Feb; 27(2):113-7. PubMed ID: 3514520 [TBL] [Abstract][Full Text] [Related]
39. Development of systemic lambda-light chain amyloidosis in a patient with gamma-heavy chain deposition disease during long-term follow-up. Komatsuda A; Maki N; Wakui H; Ohtani H; Hatakeyama T; Yasuda T; Nakamoto Y; Imai H; Sawada K Nephrol Dial Transplant; 2005 Feb; 20(2):434-7. PubMed ID: 15673693 [No Abstract] [Full Text] [Related]
40. Immunoglobulin allotypes are not involved in systemic amyloidosis. Ockhuizen T; Westra H; Bijzet J; Post J; van Leeuwen M; van Rijswijk M J Rheumatol; 1985 Aug; 12(4):742-6. PubMed ID: 3932652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]